Seoul National Univ. DMSE


Doh, Jun-Sang
Associate Professor
  • 6/2006 ~ 8/2006

    Postdoctoral Researcher, Department of Materials Science and Engineering, Massachusetts Institute of Technology

  • 9/2006 ~ 1/2008

    Postdoctoral Researcher, Department of Pathology, University of California at San Francisco

  • 2/2008 ~ 2/2019

    Assistant and Associate Professor, I-Bio/Department of Mechanical Engineering, POSTECH

  • 7/2014 ~ 3/2015

    Visiting Associate Professor, Department of Chemical and Biomolecular Engineering, University of Pennsylvania

  • 3/2019-present

    Seoul National University, Department of Materials Science and Engineering, Associate Professor

Research Interests
1. Biomaterials for cancer immunotherapy* Biomaterials controlling immune cell functions* Immune-responsive biomaterials2. Ex vivo model systems mimicking tumor-immune microenvironment* Reconstruction of 3D tumor-immune microenvironments using microfabrication* Monitoring tumor-immune interactions using biomaterial-based sensors and live cell imaging
Selected Publications
1. Books* Microfluidics in Cell Biology Part A-C, edited with Daniel Fletcher and Matthieu Piel (2018).2. Papers* Ultra-thin, aligned, free-standing nanofiber membranes to recapitulate multi-layered blood vessel/tissue interface for leukocyte infiltration studies, Biomaterials 169, 22 (2018)
* Endothelial cell focal adhesion regulates transendothelial migration and subendothelial crawling of T cells , Front. Immunol. 9, 48 (2018)
* Dynamic micropatterning of cells on nanostructured surfaces using a cell-friendly photoresist, ACS Appl. Mater. Interfaces 8, 4266 (2016) [Total of 59 publications in SCI journals]
Lab Overview
We strive to solve fundamental problems in immunology and immunotherapy by developing novel biomaterials. In particular, we are interested in cancer immunohterapy, a groundbreaking approach to treat cancer.
1. Development of smart biomaterials for the spatio-temporal control of drug deliveryIn spite of this great success, cancer immunotherapy needs to be substantially improved because still only fractions of patients are responding to the therapy as a monotherapy. To overcome this limitation, people try ‘combination’, but the problem is much more complicated than simple addition of many different therapeutics because immune responses changes over time.2. Development of ex vivo model systems for the assessment of cancer immunotherapeuticsThere is no good preclinical model for evaluation of immunotherapeutics. To overcome this limitation, we are developing various ex vivo model systems recapitulating complex immune-cancer interactions or tumor-immune microenvironments.